JP2000513351A5 - - Google Patents

Download PDF

Info

Publication number
JP2000513351A5
JP2000513351A5 JP1998502558A JP50255898A JP2000513351A5 JP 2000513351 A5 JP2000513351 A5 JP 2000513351A5 JP 1998502558 A JP1998502558 A JP 1998502558A JP 50255898 A JP50255898 A JP 50255898A JP 2000513351 A5 JP2000513351 A5 JP 2000513351A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998502558A
Other languages
English (en)
Japanese (ja)
Other versions
JP4162263B2 (ja
JP2000513351A (ja
Filing date
Publication date
Priority claimed from GBGB9613182.6A external-priority patent/GB9613182D0/en
Application filed filed Critical
Publication of JP2000513351A publication Critical patent/JP2000513351A/ja
Publication of JP2000513351A5 publication Critical patent/JP2000513351A5/ja
Application granted granted Critical
Publication of JP4162263B2 publication Critical patent/JP4162263B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50255898A 1996-06-24 1997-06-24 フリーラジカル―誘発状態を治療するためのキレート化剤およびその金属キレート Expired - Lifetime JP4162263B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
GB9613182.6 1996-06-24
PCT/GB1997/001722 WO1997049409A1 (en) 1996-06-24 1997-06-24 Chelating agents and their metal chelates for treating free radicals induced conditions

Publications (3)

Publication Number Publication Date
JP2000513351A JP2000513351A (ja) 2000-10-10
JP2000513351A5 true JP2000513351A5 (enExample) 2005-02-10
JP4162263B2 JP4162263B2 (ja) 2008-10-08

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50255798A Expired - Lifetime JP4359651B2 (ja) 1996-06-24 1997-06-24 マンガン化合物を用いた抗腫瘍剤の心臓毒性の減少
JP50255898A Expired - Lifetime JP4162263B2 (ja) 1996-06-24 1997-06-24 フリーラジカル―誘発状態を治療するためのキレート化剤およびその金属キレート

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50255798A Expired - Lifetime JP4359651B2 (ja) 1996-06-24 1997-06-24 マンガン化合物を用いた抗腫瘍剤の心臓毒性の減少

Country Status (14)

Country Link
US (2) US6147094A (enExample)
EP (2) EP0910360B1 (enExample)
JP (2) JP4359651B2 (enExample)
CN (2) CN1228694A (enExample)
AT (2) ATE225178T1 (enExample)
AU (2) AU720570B2 (enExample)
BR (1) BR9709942A (enExample)
CA (2) CA2258299A1 (enExample)
DE (2) DE69716104T2 (enExample)
GB (1) GB9613182D0 (enExample)
IL (1) IL127733A0 (enExample)
NO (2) NO985916L (enExample)
NZ (2) NZ333357A (enExample)
WO (2) WO1997049409A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1770299A (en) 1997-12-23 1999-07-19 Nycomed Imaging As Nitric oxide releasing chelating agents and their therapeutic use
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
KR20100075503A (ko) 1999-10-01 2010-07-02 디엠아이 바이오사이언시스, 인크 금속 결합 화합물 및 그의 용도
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2823977B1 (fr) 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) * 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
EP2407169A1 (en) 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
SI1931321T1 (sl) 2005-08-31 2019-07-31 Abraxis Bioscience, Llc Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva
US8377969B2 (en) 2007-12-14 2013-02-19 Pledpharma Ab Compounds for use in the treatment of cancer
RU2563825C2 (ru) 2009-07-06 2015-09-20 Пледфарма Аб Фармацевтические композиции и терапевтические способы, в которых применяется комбинация комплексного соединения марганца и соединения в форме, не являющейся марганцевым комплексом
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
ES2683038T3 (es) 2012-01-05 2018-09-24 Pledpharma Ab Calmangafodipir, una nueva entidad química, y otros complejos metálicos mixtos, métodos de preparación, composiciones y métodos de tratamiento
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
BR112015009963A2 (pt) 2012-11-02 2017-07-11 Pledpharma Ab uso de compostos para a preparação de composições farmacêuticas para o tratamento de câncer
US20160250351A1 (en) 2014-06-13 2016-09-01 Mayo Foundation For Medical Education And Research Treating Lymphomas
CN106604750B (zh) 2014-06-16 2021-05-07 梅约医学教育与研究基金会 治疗骨髓瘤
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
AU2017238119A1 (en) * 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
WO2017165439A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018045238A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체-pd-l1 결합제 조성물
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル-アルブミン-結合剤組成物並びに該組成物の使用及び製造方法
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2001502742A5 (enExample)
JP2000501771A5 (enExample)
JP2001504330A5 (enExample)
JP2000501599A5 (enExample)
JP2001504720A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000507722A5 (enExample)
JP2000502485A5 (enExample)
JP2001504644A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000502570A5 (enExample)
JP2001500441A5 (enExample)
JP2000501876A5 (enExample)
JP2000513351A5 (enExample)
JP2000501744A5 (enExample)
JP2000514044A5 (enExample)
JP2000502316A5 (enExample)
JP2001509329A5 (enExample)
JP2000502714A5 (enExample)
JP2002514082A5 (enExample)
JP2000502479A5 (enExample)